ACADIA Pharmaceuticals Inc. (ACAD)
After hours:
| Previous close | 16.31 |
| Open | 16.42 |
| Bid | 16.69 x 500 |
| Ask | 16.72 x 1100 |
| Day's range | 16.26 - 16.74 |
| 52-week range | 16.16 - 33.99 |
| Volume | |
| Avg. volume | 1,799,645 |
| Market cap | 2.753B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.37 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.29 |
Business WireAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
SAN DIEGO, April 24, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.
Business WireAcadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
SAN DIEGO, April 22, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission.
Business WireAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 19, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units ("RSUs") to six new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employme
